Ceraso A, Lin JJ, Schneider-Thoma J et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2020; (8): CD008016.
Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). S3-Leitlinie Schizophrenie (Living Guideline). AWMF register no.: 038-009. 2025.
Fountoulakis KN, Stahl SM. The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: A systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment arms. J Psychopharmacol 2022; 36(4): 428-438.
Galling B, Roldan A, Hagi K et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017; 16(1): 77-89.
Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394(10202): 939-951.
Huhtaniska S, Jääskeläinen E, Hirvonen N et al. Long-term antipsychotic use and brain changes in schizophrenia - a systematic review and meta-analysis. Hum Psychopharmacol 2017; 32(2).
Jia N, Li Z, Li X et al. Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis. Rev Bras Psiquiatr 2022; 44(6): 664–673.
Leucht S, Leucht C, Huhn M et al. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry 2017; 174(10): 927-942.
Leucht S, Vauth R, Olbrich HM et al. Schizophrenien und andere psychotische Störungen. In: Psychische Erkrankungen - Klinik und Therapie. Munich: Urban und Fischer; 2015.
Lochmann van Bennekom MW, IntHout J, Gijsman HJ et al. Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data. Schizophr Res 2024; 272: 1-11.
McDonagh MS, Dana T, Selph S et al. Treatments for Schizophrenia in Adults: A Systematic Review (AHQR Comparative Effectiveness Reviews; No. 198). 2017.
Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE et al. Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev 2017; (6): CD009005.
Ostuzzi G, Vita G, Bertolini F et al. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. Lancet Psychiatry 2022; 9(8): 614-624.
Rubio JM, Schoretsanitis G, John M et al. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. Lancet Psychiatry 2020; 7(9): 749-761.
Schneider-Thoma J, Chalkou K, Dorries C et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet 2022; 399(10327): 824-836.
IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.